戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 a alone, blocked the induction of IGFBP-6 by bexarotene.
2 versus physician's choice of methotrexate or bexarotene.
3 d atorvastatin 10 mg orally beginning before bexarotene.
4 sistant patients received both tamoxifen and bexarotene.
5 duced RXR heterodimer activation compared to bexarotene.
6 verse events and withdrawals attributable to bexarotene.
7 ntify a novel autophagy-modulating effect of bexarotene.
8 sition significantly affects the response to bexarotene.
9 urons, and APOE3 and APOE4 mice treated with bexarotene.
10 urons, and APOE3 and APOE4 mice treated with bexarotene.
11 r protein kinase B (Akt) was also blunted by bexarotene.
12 at PPARgamma is necessary for the effects of bexarotene.
13 to improved cognition and memory elicited by bexarotene.
14 -tetrahydro-2-naphthyl)ethynyl]benzoic acid (bexarotene, 1) as well as seven novel and two reported a
15 l methotrexate 5-50 mg once per week or oral bexarotene 300 mg/m(2) once per day) for up to 48 weeks.
16 nce status 0 to 1, were randomly assigned to bexarotene 400 mg/m(2)/d combined with carboplatin and p
17                                              Bexarotene 400 mg/m2 orally was to be administered conti
18 ed phase II doses are erlotinib 150 mg/d and bexarotene 400 mg/m2/d orally.
19 luded a platinum and a taxane, received oral bexarotene 400 mg/m2/d plus concomitant levothyroxine an
20 ous T-cell lymphoma with escalating doses of bexarotene (75 mg/day-300 mg/day) and denileukin diftito
21               We investigated the effects of bexarotene (a retinoid X receptor agonist), CD1530 (a re
22 t Nurr1 can be pharmacologically targeted by bexarotene, a ligand for the retinoid X receptor that fo
23 urr1 could be pharmacologically targeted via bexarotene, a ligand of Nurr1's heterodimerization partn
24            Previous studies of the retinoid, bexarotene, a retinoid X receptor-specific ligand, have
25                                              Bexarotene, a selective agonist for Retinoid X receptors
26                    Here, we demonstrate that bexarotene, a T-cell lymphoma medication with known anti
27 xamined the signaling pathways that transmit bexarotene action in the context of myoblast differentia
28                                              Bexarotene-activated retinoid X receptors (RXRs) amelior
29   In vitro data from ES cells confirmed that bexarotene-activated RXR affected neuronal development a
30                             We conclude that bexarotene-activated RXRs promote genetic programs invol
31             These newly described actions of bexarotene add to the growing amount of compelling data
32 ts in the first two groups were treated with bexarotene alone, whereas the tamoxifen-resistant patien
33                                              Bexarotene also decreased angiotensin II-mediated inflam
34                                              Bexarotene also induced mRNA and protein levels for pero
35                                              Bexarotene also restored mitochondrial respiration defic
36                          In primary neurons, bexarotene ameliorated the damaged dendrite complexity a
37  first time the neuroprotective potential of bexarotene, an FDA-approved agent, in a co-morbidity mod
38 hanism of action, reduction of ROS, by which bexarotene and CD1530 inhibit carcinogenesis.
39 nduces apoptosis that is further enhanced by bexarotene and decreases the PPAR-gamma and bcl-xL prote
40  responded rapidly to combination therapy of bexarotene and interferon (IFN)-alpha2b with complete cl
41                   Five (19%) participants on bexarotene and two (8%) on placebo discontinued the stud
42 h UVA or UVB), topical chemotherapy, topical bexarotene, and radiotherapy including total skin electr
43 )ethynyl]benzoic acid (1), commonly known as bexarotene, and their analysis in acting as retinoid X r
44                                        Thus, bexarotene appears to be an effective preventive agent a
45 ated and that even low doses (150 mg/day) of bexarotene are capable of in vivo upregulation of CD25 e
46 lgia, and diarrhea were more frequent in the bexarotene arm.
47 e of an agonist to the nuclear receptor RXR, bexarotene, as monotherapy against AD, presents potentia
48 ethynyl]benzoic acid (1), otherwise known as bexarotene, as well as four novel analogues of (E)-3-(3-
49 all groups were randomly assigned to receive bexarotene at either 200 or 500 mg/m(2)/d.
50 ho were enrolled in trials of high-dose oral bexarotene at one institution.
51 that the retinoid X receptor (RXR) retinoid, bexarotene, at biologically relevant concentrations of 1
52                                              Bexarotene augmented CDDO-induced apoptosis in these cel
53                                              Bexarotene (BEX) is a retinoid that induce the expressio
54    Meanwhile, the treatment with RXR agonist bexarotene (BEX) reversed the signature genes of microgl
55               Previous data demonstrate that bexarotene (Bex), retinoid X receptor (RXR) agonist, red
56             Targeting TR4 with an antagonist bexarotene (Bex, a derivative of retinoid) suppressed th
57             Compared with dimethylsulfoxide, bexarotene blocked angiotensin II-induced SM contractile
58 nts in biological potency and selectivity of bexarotene can be achieved through rational drug design.
59                                              Bexarotene can be safely added to platinum-based chemoth
60                       The data indicate that bexarotene can resensitize gemcitabine-resistant tumor c
61 ) that treatment of APP/PS1DeltaE9 mice with bexarotene decreased Abeta pathology and ameliorated mem
62 trast to the market-approved pan-RXR agonist bexarotene, did not elevate triglyceride levels, indicat
63  IL-2R expression was observed at or above a bexarotene dose of 150 mg/day.
64                                     In vivo, bexarotene dose-dependently inhibited TNF-alpha-induced
65                                     Although bexarotene elevated triglycerides and cholesterol in the
66              Following thromboembolic stroke bexarotene enhanced autophagy in the ischemic brain conc
67                     Combining erlotinib with bexarotene enhanced growth suppression in vitro compared
68                          In primary neurons, bexarotene enhanced the dendritic complexity characteriz
69                    Furthermore, the model of bexarotene-enhanced myogenic differentiation will provid
70 osahexaenoic acid (DHA), in combination with bexarotene, enhances LXR:RXR target gene expression of A
71                As an additional benefit, the bexarotene fibrils kill primary rat hippocampal neurons
72 of CDDO, either alone or in combination with bexarotene for MF/SS patients.
73           In the intent-to-treat population, bexarotene given as third or subsequent line of therapy
74                    In the therapeutic model, bexarotene gradually resensitized Calu3-GemR cells to ge
75 transfer ratio was not different between the bexarotene group (0.25 percentage units [pu; SD 0.98]) a
76 y of lung tumors compared to the control and bexarotene groups.
77 ter in patients treated with higher doses of bexarotene (>300 mg per square meter of body-surface are
78                                              Bexarotene had a greater effect on calponin reduction, M
79                    Participants who received bexarotene had a higher mean number of adverse events (6
80                                              Bexarotene has also been evaluated in clinical trials fo
81     However, the chemopreventive efficacy of bexarotene has not been determined in mouse lung cancer
82                                              Bexarotene has shown efficacy in a phase I/II trial of n
83 n in rats in vivo, the results revealed that bexarotene has the capacity to coregulate subsets of Nur
84 onstrated efficacy of the oral RXR retinoid, bexarotene, has altered the treatment paradigm of early-
85  promising and warrant further evaluation of bexarotene in advanced NSCLC.
86 d effects of the retinoid X receptor agonist bexarotene in an aggressive model of AD.
87                  Conclusion: The efficacy of bexarotene in patients with refractory metastatic breast
88  may represent a mechanism for resistance to bexarotene in T-cell malignancies.
89  expression profile (RNA-Seq) in response to bexarotene in the cortex of APOE4 mice.
90 findings establish the viability of applying bexarotene in the prevention and treatment of muscle-was
91 We evaluated the efficacy and safety of oral bexarotene in the treatment of patients with metastatic
92 ) Versus Physician's Choice [Methotrexate or Bexarotene] in Participants With CD30-Positive Cutaneous
93                                     We found bexarotene increased RXR binding to promoter regions in
94                          In in vitro studies bexarotene increased the expression of autophagy markers
95            In chromatin binding experiments, bexarotene increased the occupancy of the identified enh
96              This investigation reveled that bexarotene increases the mRNA and protein levels of ABCA
97 kout cells demonstrated blunted responses to bexarotene, indicating that PPARgamma is necessary for t
98                         We demonstrated that bexarotene induced apoptosis of the patient's malignant
99 ne marks H3K4me3 and H3K27me3 revealed that, bexarotene induced epigenetic changes, consistent with i
100  blood malignant T cells became resistant to bexarotene-induced apoptosis.
101 have been extended in patients who developed bexarotene-induced hypertriglyceremia and/or skin rash.
102 al was significantly longer in patients with bexarotene-induced hypertriglyceridemia and/or skin rash
103                      Moreover, DHA abrogates bexarotene-induced hypertriglyceridemia in vivo.
104                                              Bexarotene inhibited both tumor multiplicity and tumor v
105  advanced-stage disease (IIB-IV) and include bexarotene, interferon alpha, extracorporeal photopheres
106  with combined extracorporeal photopheresis, bexarotene, interferon-y, and low-dose TSEBT.
107                                              Bexarotene is a drug already used clinically to treat ca
108 owing amount of compelling data showing that bexarotene is a potent neuroprotective agent, and identi
109                                     Purpose: Bexarotene is a retinoid X receptor-selective retinoid t
110                                              Bexarotene is an RXR-selective retinoid that can induce
111 ind that the suppression of fibril growth by bexarotene is not because of the drug binding to the fib
112 t the combination of denileukin diftitox and bexarotene is well tolerated and that even low doses (15
113                                     LGD1069 (Bexarotene) is a potent RXR-selective retinoid with redu
114    The only currently FDA-approved rexinoid, bexarotene, is ineffective as a single agent for treatin
115 ith the retinoid X receptor-selective ligand bexarotene led us to hypothesize that such ligands could
116                   The rexinoids LG100268 and bexarotene (LG1069, Targretin) were highly efficacious i
117 ries enriched in both datasets revealed that bexarotene-liganded RXR affected signaling pathways asso
118 ted with increased survival, suggesting that bexarotene may benefit a segment of first-line NSCLC pat
119                           This suggests that bexarotene may have clinical utility in cancers where dr
120 For the 146 assessable patients treated with bexarotene, median age was 66 years (range, 34 to 87 yea
121 cell lymphoma who are treated with high-dose bexarotene, most likely because the retinoid X receptor-
122 nts were randomly assigned to receive either bexarotene (n=26) or placebo (n=26).
123 d the effects of CDDO and its synergism with bexarotene on apoptosis in MF/SS cell lines (MJ, Hut78,
124 ides originate from the liver, the effect of bexarotene on lipogenesis in breast epithelial cells is
125  investigated the effects of the RXR agonist bexarotene on mRNA and protein levels of apoE, ABCA1, an
126             Here we examine if the effect of bexarotene on RXR cistrome and transcriptomes depend on
127  were pretreated with either an RXR agonist (bexarotene or 9-cis retinoic acid) or vehicle (dimethyls
128  endothelial cells with RXR agonists such as bexarotene or 9-cis-retinoid acid.
129                While monotherapy with either bexarotene or DHA resulted in modest effects in vitro an
130 mg/m(2) of body surface area per day of oral bexarotene or oral placebo for 6 months.
131              Exposure to 10(-6) to 10(-10) M bexarotene or Panretin for 48 hours was associated with
132 e to 0.05 mU per liter during treatment with bexarotene (P<0.001), and the mean serum free thyroxine
133                                              Bexarotene patients also received lipid-lowering agents
134  the placebo group (0.09 pu [0.84]; adjusted bexarotene-placebo difference 0.16 pu, 95% CI -0.39 to 0
135  the 4-NQO plus CD1530 (4N+C) and 4-NQO plus bexarotene plus CD1530 (4N+B+C) groups compared with the
136 lar effects on the RXR LBD conformation than bexarotene possibly mediating the selective activity.
137                                    Moreover, bexarotene pretreatment improved neuron survival in prim
138                                 We show that bexarotene promotes myoblast differentiation and fusion
139                  Cramer et al. reported that bexarotene rapidly reduces beta-amyloid (Abeta) levels a
140                                 Furthermore, bexarotene reduced the progression of adenoma to adenoca
141                 We now report that, although bexarotene reduces soluble Abeta40 levels in one of the
142                                      Whereas bexarotene regulates fundamental biological processes th
143 tients (14%) discontinued therapy because of bexarotene-related toxicity.
144                                The rexinoid, bexarotene, represses cyclin D1 and EGFR expression in v
145 k treatment of 3.5 month old 5XFAD mice with bexarotene resulted in the clearance of intraneuronal am
146                                 Furthermore, bexarotene reversed the apoE4-driven accumulation of Abe
147 treatment of apoE4 mice with the RXR agonist bexarotene reverses the apoE4-induced cognitive and neur
148 e provide evidence that retinoids, including Bexarotene, selectively induce CTCL lineages to increase
149 XR-alpha expression compared with pretherapy bexarotene-sensitive cells.
150                               Interestingly, bexarotene signaling appears to correlate with residue-s
151                                     Although bexarotene significantly (p < 0.01) elevated plasma trig
152 firmed by in vivo studies demonstrating that bexarotene significantly improved the compromised dendri
153                                 Furthermore, bexarotene stimulated the rapid reversal of cognitive, s
154 ate and validate our central conclusion that bexarotene stimulates the clearance of soluble beta-amyl
155  of the PPARgamma agonist rosiglitazone with bexarotene synergistically suppressed the growth of huma
156 rystal structures of these new rexinoids and bexarotene (Targretin) bound to hRXRalpha-LBD, we reveal
157                            The oral rexinoid bexarotene (Targretin) is widely used for treatment of c
158                                              Bexarotene (Targretin), is a synthetic high-affinity RXR
159                       The synthetic rexinoid bexarotene (Targretin, LGD1069) inhibits the formation o
160 e whether addition of the synthetic rexinoid bexarotene (Targretin; Eisai Inc, Woodcliff Lake, NJ) to
161                                              Bexarotene (Targretin; Ligand Pharmaceuticals, Inc, San
162                   However, with inclusion of bexarotene, the cells remained chemosensitive.
163       Oral administration of the RXR agonist bexarotene to a mouse model of AD resulted in enhanced c
164                     Although the addition of bexarotene to chemotherapy did not improve survival in t
165                                  We compared bexarotene to five agonists of nuclear receptors (PPARal
166 s study, we have investigated the ability of bexarotene to inhibit lung tumor progression in the muta
167             Here, we evaluate the ability of bexarotene to modulate the acquisition and maintenance o
168               We do not recommend the use of bexarotene to treat patients with multiple sclerosis bec
169                                          All bexarotene-treated participants had at least one adverse
170 rrence of high-grade hypertriglyceridemia in bexarotene-treated patients strongly correlated with inc
171 ever, a subpopulation (approximately 40%) of bexarotene-treated patients who experienced National Can
172                                              Bexarotene-treated patients with grade 3/4 hypertriglyce
173 liferating cells compared to the control and bexarotene-treated tumors.
174                                              Bexarotene treatment at a dose of 250 mg/kg diet was ass
175        Cramer et al. demonstrates short-term bexarotene treatment clearing preexisting beta-amyloid d
176 mic adverse effects associated with standard bexarotene treatment from the antiproliferative effects
177                                    Moreover, bexarotene treatment improved remote memory stabilizatio
178 creased number of neuronal progenitors after bexarotene treatment in the dentate gyrus of APOE3 and A
179 roliferation and apoptosis were modulated by bexarotene treatment independently of estrogen signaling
180 llectively, these data provide evidence that bexarotene treatment reduced neuron loss, elevated level
181 induced by Abeta42 in vitro was inhibited by bexarotene treatment.
182 econdary to renal insufficiency unrelated to bexarotene treatment.
183 d cytoplasmic lipid droplets after long-term bexarotene treatment.
184 mic therapies at least one of which included bexarotene unless intolerable.
185                                              Bexarotene, used to treat cutaneous T cell lymphoma, is
186                                    Moreover, bexarotene was able to restore dysfunctional Ret-depende
187 o gemcitabine but were growth inhibited when bexarotene was added to the cytotoxic agent.
188     In the phase I portion, the daily MTD of bexarotene was determined to be 400 mg/m2.
189     Once the maximum-tolerated dose (MTD) of bexarotene was determined, the study entered the phase I
190    In the phase I portion, the daily dose of bexarotene was escalated in cohorts of three patients fr
191                                              Bexarotene was given by gavage starting at 16 weeks afte
192          Although our data demonstrated that bexarotene was ineffective in neuroprotection in rats in
193 for non-small-cell lung cancer, the rexinoid bexarotene was most effective for patients who developed
194 tients became euthyroid after treatment with bexarotene was stopped.
195                      The salutary effects of bexarotene were accompanied by reduced plaque burden, de
196 the remaining patients, adverse reactions to bexarotene were generally mild to moderate.
197                                  The agonist bexarotene, when used in concentrations achievable in hu
198 rillar species and an aggregation inhibitor, bexarotene, which is able to prevent AB42 aggregation in
199        In this phase I/II trial, we combined bexarotene with cisplatin and vinorelbine in the treatme
200             In patients with advanced NSCLC, bexarotene with cisplatin and vinorelbine yielded accept
201           It was hypothesized that combining bexarotene with the EGFR inhibitor, erlotinib, would aug
202 It is noteworthy that combining low doses of bexarotene with the PPARgamma agonist rosiglitazone prov

 
Page Top